JP2024542523A - 神経変性障害の治療選択及び治療 - Google Patents
神経変性障害の治療選択及び治療 Download PDFInfo
- Publication number
- JP2024542523A JP2024542523A JP2024530556A JP2024530556A JP2024542523A JP 2024542523 A JP2024542523 A JP 2024542523A JP 2024530556 A JP2024530556 A JP 2024530556A JP 2024530556 A JP2024530556 A JP 2024530556A JP 2024542523 A JP2024542523 A JP 2024542523A
- Authority
- JP
- Japan
- Prior art keywords
- weeks
- disease
- gene
- subject
- disorder associated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163282615P | 2021-11-23 | 2021-11-23 | |
| US63/282,615 | 2021-11-23 | ||
| US202263393573P | 2022-07-29 | 2022-07-29 | |
| US63/393,573 | 2022-07-29 | ||
| PCT/US2022/050940 WO2023097029A1 (en) | 2021-11-23 | 2022-11-23 | Therapy selection and treatment of neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024542523A true JP2024542523A (ja) | 2024-11-15 |
| JP2024542523A5 JP2024542523A5 (https=) | 2025-12-03 |
Family
ID=86540341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024530556A Pending JP2024542523A (ja) | 2021-11-23 | 2022-11-23 | 神経変性障害の治療選択及び治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240417798A1 (https=) |
| EP (1) | EP4436573A4 (https=) |
| JP (1) | JP2024542523A (https=) |
| AU (1) | AU2022396274A1 (https=) |
| CA (1) | CA3237579A1 (https=) |
| WO (1) | WO2023097029A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025054599A1 (en) * | 2023-09-08 | 2025-03-13 | Anavex Life Sciences Corp. | Treatment and prevention of cerebral atrophy |
| WO2025117826A1 (en) * | 2023-11-30 | 2025-06-05 | Anavex Life Sciences Corp. | Methods of using surrogate biomarkers in sigma-1 receptor therapy |
| CN117679516A (zh) * | 2023-12-13 | 2024-03-12 | 广东工业大学 | Ndufa7基因在制备改善和/或治疗线粒体功能障碍相关疾病的药物中的应用 |
| WO2025231180A1 (en) * | 2024-05-01 | 2025-11-06 | Anavex Life Sciences Corp. | Blarcamesine correction of eeg biomarkers in fragile x syndrome |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7476103B1 (en) * | 2005-10-17 | 2009-01-13 | Penelope Anne Norman | Science party kit and method |
| CN106501251A (zh) * | 2016-12-09 | 2017-03-15 | 防城港市质量技术监督局 | 一种用于检测大麻油的试剂盒 |
| WO2019089988A1 (en) * | 2017-11-01 | 2019-05-09 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| AU2019269739B2 (en) * | 2018-05-18 | 2025-12-18 | Anavex Life Sciences Corp. | Optimized sigma-1 agonist method of responder selection and treatment |
| US12352767B2 (en) * | 2018-07-16 | 2025-07-08 | University Of Virginia Patent Foundation | Method of treating cognitive decline associated with neurological diseases based on a decrease in FLT4 expression or activity |
-
2022
- 2022-11-23 WO PCT/US2022/050940 patent/WO2023097029A1/en not_active Ceased
- 2022-11-23 US US18/712,387 patent/US20240417798A1/en active Pending
- 2022-11-23 AU AU2022396274A patent/AU2022396274A1/en active Pending
- 2022-11-23 EP EP22899408.3A patent/EP4436573A4/en active Pending
- 2022-11-23 JP JP2024530556A patent/JP2024542523A/ja active Pending
- 2022-11-23 CA CA3237579A patent/CA3237579A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240417798A1 (en) | 2024-12-19 |
| EP4436573A4 (en) | 2026-01-21 |
| CA3237579A1 (en) | 2023-06-01 |
| WO2023097029A1 (en) | 2023-06-01 |
| EP4436573A1 (en) | 2024-10-02 |
| AU2022396274A1 (en) | 2024-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024542523A (ja) | 神経変性障害の治療選択及び治療 | |
| EP2559434A2 (en) | Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist | |
| JP4993523B2 (ja) | 20(s)−プロトパナキサジオールの抗うつ薬製造への使用 | |
| EP4297871A1 (en) | Methods and compositions for treating agitation | |
| JP2022514194A (ja) | 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール | |
| WO2016179097A1 (en) | Methods for treating mitochondrial damage diseases | |
| KR20180051561A (ko) | 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법 | |
| KR20180097581A (ko) | 1-(3-(2-(1-벤조티오펜-5-일)에톡시)프로필)아제티딘-3-올 또는 그 염을 포함하는 정제 | |
| JP2025501646A (ja) | Gm2ガングリオシドーシスの処置 | |
| KR102527378B1 (ko) | 2'-fl을 함유하는 도파민 감소로 말미암아 발생하는 질환의 개선, 예방 또는 치료용 조성물 | |
| US20240131038A1 (en) | Anti-inflammatory compositions comprising cannabidiol, delta-9-tetrahydrocannabinol and linalool | |
| JP7744419B2 (ja) | レット症候群を治療するためのプリドピジンまたはその類似体の使用 | |
| AU2023314929A1 (en) | Therapy selection and treatment of neurodegenerative disorders | |
| CN118613282A (zh) | 神经退行性病症的疗法选择和治疗 | |
| WO2023192372A1 (en) | Methods of treating sjögren-larssen syndrome | |
| EP4284359A1 (en) | Methods and compositions for preventing or reducing neuroinflammation | |
| WO2025117826A1 (en) | Methods of using surrogate biomarkers in sigma-1 receptor therapy | |
| CN105748460B (zh) | 一种治疗老年痴呆的药物 | |
| EP4591861A1 (en) | Use of 4-tmap for treating or relieving depression | |
| WO2020188569A1 (en) | Methods and compositions for preventing or treating weight gain caused by psychiatric drugs | |
| WO2025231180A9 (en) | Blarcamesine correction of eeg biomarkers in fragile x syndrome | |
| WO2025264845A1 (en) | Use of anavex3-71 for medical treatments | |
| WO2025054599A1 (en) | Treatment and prevention of cerebral atrophy | |
| WO2025240562A1 (en) | Method of treating amyotrophic lateral sclerosis with trimetazidine | |
| WO2026015656A1 (en) | Responder selection and treatment with sigma-1 receptor therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251125 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251125 |